Research ArticleSystemic Lupus Erythematosus
High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis
Taro Iwamoto, Jessica M. Dorschner, Shanmugapriya Selvaraj, Valeria Mezzano, Mark A. Jensen, Danielle Vsetecka, Shreyasee Amin, Ashima Makol, Thomas Osborn, Kevin Moder, Vaidehi R. Chowdhary, Peter Izmirly, H. Michael Belmont, Robert M. Clancy, Jill P. Buyon, Ming Wu, Cynthia A. Loomis and Timothy B. Niewold
The Journal of Rheumatology April 2022, 49 (4) 388-397; DOI: https://doi.org/10.3899/jrheum.210391
Taro Iwamoto
1T. Iwamoto, MD, PhD, Colton Center for Autoimmunity, New York University, New York, New York, USA, and Allergy and Clinical Immunology, Chiba University, Japan;
Jessica M. Dorschner
2J.M. Dorschner, BS, D. Vsetecka, MPH, S. Amin, MD, A. Makol, MD, T. Osborn, MD, K. Moder, MD, V.R. Chowdhary, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, USA;
Shanmugapriya Selvaraj
3S. Selvaraj, MS, V. Mezzano, MD, PhD, M. Wu, MD, C.A. Loomis, MD, PhD, Department of Pathology, New York University, New York, New York, USA;
Valeria Mezzano
3S. Selvaraj, MS, V. Mezzano, MD, PhD, M. Wu, MD, C.A. Loomis, MD, PhD, Department of Pathology, New York University, New York, New York, USA;
Mark A. Jensen
4M.A. Jensen, PhD, R.M. Clancy, PhD, J.P. Buyon, MD, T.B. Niewold, MD, Colton Center for Autoimmunity, New York University, New York, New York, USA;
Danielle Vsetecka
2J.M. Dorschner, BS, D. Vsetecka, MPH, S. Amin, MD, A. Makol, MD, T. Osborn, MD, K. Moder, MD, V.R. Chowdhary, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, USA;
Shreyasee Amin
2J.M. Dorschner, BS, D. Vsetecka, MPH, S. Amin, MD, A. Makol, MD, T. Osborn, MD, K. Moder, MD, V.R. Chowdhary, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, USA;
Ashima Makol
2J.M. Dorschner, BS, D. Vsetecka, MPH, S. Amin, MD, A. Makol, MD, T. Osborn, MD, K. Moder, MD, V.R. Chowdhary, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, USA;
Thomas Osborn
2J.M. Dorschner, BS, D. Vsetecka, MPH, S. Amin, MD, A. Makol, MD, T. Osborn, MD, K. Moder, MD, V.R. Chowdhary, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, USA;
Kevin Moder
2J.M. Dorschner, BS, D. Vsetecka, MPH, S. Amin, MD, A. Makol, MD, T. Osborn, MD, K. Moder, MD, V.R. Chowdhary, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, USA;
Vaidehi R. Chowdhary
2J.M. Dorschner, BS, D. Vsetecka, MPH, S. Amin, MD, A. Makol, MD, T. Osborn, MD, K. Moder, MD, V.R. Chowdhary, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, USA;
Peter Izmirly
5P. Izmirly, MD, H.M. Belmont, MD, Division of Rheumatology, New York University, New York, New York, USA.
H. Michael Belmont
5P. Izmirly, MD, H.M. Belmont, MD, Division of Rheumatology, New York University, New York, New York, USA.
Robert M. Clancy
4M.A. Jensen, PhD, R.M. Clancy, PhD, J.P. Buyon, MD, T.B. Niewold, MD, Colton Center for Autoimmunity, New York University, New York, New York, USA;
Jill P. Buyon
4M.A. Jensen, PhD, R.M. Clancy, PhD, J.P. Buyon, MD, T.B. Niewold, MD, Colton Center for Autoimmunity, New York University, New York, New York, USA;
Ming Wu
3S. Selvaraj, MS, V. Mezzano, MD, PhD, M. Wu, MD, C.A. Loomis, MD, PhD, Department of Pathology, New York University, New York, New York, USA;
Cynthia A. Loomis
3S. Selvaraj, MS, V. Mezzano, MD, PhD, M. Wu, MD, C.A. Loomis, MD, PhD, Department of Pathology, New York University, New York, New York, USA;
Timothy B. Niewold
4M.A. Jensen, PhD, R.M. Clancy, PhD, J.P. Buyon, MD, T.B. Niewold, MD, Colton Center for Autoimmunity, New York University, New York, New York, USA;
REFERENCES
- 1.↵
- 2.↵
- 3.↵
- Izmirly PM,
- Wan I,
- Sahl S, et al.
- 4.↵
- 5.↵
- 6.↵
- 7.↵
- 8.↵
- 9.↵
- Blanco P,
- Palucka AK,
- Gill M,
- Pascual V,
- Banchereau J.
- 10.↵
- 11.↵
- 12.↵
- 13.↵
- 14.↵
- 15.↵
- 16.↵
- 17.↵
- Niewold TB,
- Kelly JA,
- Kariuki SN, et al.
- 18.↵
- 19.↵
- 20.↵
- 21.↵
- Baechler EC,
- Batliwalla FM,
- Karypis G, et al.
- 22.↵
- 23.↵
- 24.↵
- 25.↵
- 26.↵
- 27.↵
- Weening JJ,
- D’Agati VD,
- Schwartz MM, et al.
- 28.↵
- Mina R,
- Abulaban K,
- Klein-Gitelman MS, et al.
- 29.↵
- 30.↵
- 31.↵
- 32.↵
- 33.↵
- Kim JM,
- Wu H,
- Green G, et al.
- 34.↵
- 35.↵
- 36.↵
- 37.↵
- 38.↵
- 39.↵
- 40.↵
- Paredes JL,
- Niewold TB.
In this issue
The Journal of Rheumatology
Vol. 49, Issue 4
1 Apr 2022
High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis
Taro Iwamoto, Jessica M. Dorschner, Shanmugapriya Selvaraj, Valeria Mezzano, Mark A. Jensen, Danielle Vsetecka, Shreyasee Amin, Ashima Makol, Thomas Osborn, Kevin Moder, Vaidehi R. Chowdhary, Peter Izmirly, H. Michael Belmont, Robert M. Clancy, Jill P. Buyon, Ming Wu, Cynthia A. Loomis, Timothy B. Niewold
The Journal of Rheumatology Apr 2022, 49 (4) 388-397; DOI: 10.3899/jrheum.210391
High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis
Taro Iwamoto, Jessica M. Dorschner, Shanmugapriya Selvaraj, Valeria Mezzano, Mark A. Jensen, Danielle Vsetecka, Shreyasee Amin, Ashima Makol, Thomas Osborn, Kevin Moder, Vaidehi R. Chowdhary, Peter Izmirly, H. Michael Belmont, Robert M. Clancy, Jill P. Buyon, Ming Wu, Cynthia A. Loomis, Timothy B. Niewold
The Journal of Rheumatology Apr 2022, 49 (4) 388-397; DOI: 10.3899/jrheum.210391